Application of immunosignatures to the assessment of Alzheimer's disease

Authors

  • Lucas Restrepo MD, MS,

    1. Center for Innovations in Medicine, Biodesign Institute, Arizona State University, Tempe, AZ
    2. Molecular and Cell Biology Program, Arizona State University, Tempe, AZ
    3. School of Life Sciences, Arizona State University, Tempe, AZ
    Search for more papers by this author
  • Phillip Stafford PhD,

    1. Center for Innovations in Medicine, Biodesign Institute, Arizona State University, Tempe, AZ
    Search for more papers by this author
  • D. Mitch Magee PhD,

    1. Center for Innovations in Medicine, Biodesign Institute, Arizona State University, Tempe, AZ
    Search for more papers by this author
  • Stephen Albert Johnston PhD

    Corresponding author
    1. Center for Innovations in Medicine, Biodesign Institute, Arizona State University, Tempe, AZ
    2. School of Life Sciences, Arizona State University, Tempe, AZ
    • Center for Innovations in Medicine, The Biodesign Institute, Arizona State University, Tempe, AZ 85287-5901
    Search for more papers by this author

  • Potential conflict of interest: All authors were funded by grants received from the Arizona Alzheimer's Consortium, the Alzheimer's Drug Discovery Foundation (ADDF), and startup funds from the Technology Research Initiative Fund of Arizona (to S.A.J.). S.A.J. and P.S. also have a patent pending.

Abstract

Objective:

Accurate assessment of Alzheimer's disease (AD), both presymptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD. Here we explore the ability of an antibody-profiling technology to characterize AD and screen for peptides that may be used for a simple diagnostic test.

Methods:

We developed an array-based system to profile the antibody repertoire of transgenic mice with cerebral amyloidosis (TG) and elderly individuals with or without AD. The array consists of 10,000 random sequence peptides (20-mers) capable of detecting antibody binding patterns, allowing the identification of peptides that mimic epitopes targeted by a donor's serum.

Results:

TG mice exhibited a distinct immunoprofile compared to nontransgenic littermates. Further, we show that dementia patients, including autopsy-confirmed AD subjects, have distinguishable profiles compared to age-matched nondemented people. Using antibodies to different forms of Aβ peptide and blocking protocols, we demonstrate that most of this signature is not due to the subject's antibodies raised against Aβ.

Interpretation:

We propose that “immunosignaturing” technology may have potential as a diagnostic tool in AD. ANN NEUROL 2011;

Ancillary